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Objective: Soluble mediators in synovial ﬂuid (SF) are acknowledged as key players in the pathophysi-
ology of osteoarthritis (OA). However, a wide-spectrum screening of such mediators in SF is currently
lacking. In this study, the levels of 47 mediators in the SF of control donors and osteoarthritic (OA)
patients were compared.
Materials & Methods: SFwas collected from control donors (n¼ 16) and end-stage knee OA patients (n¼ 18)
and analysed for 47 cytokines, chemokines and growth factors using several multiplex enzyme-linked
immunosorbent assays (ELISAs). A ManneWhitney U test was used to determine differences between OA
and control controls. A principal component analysis (PCA) was performed to cluster the 47 mediators.
Results: The majority of the mediators could be detected in both control and OA SF. Interleukin (IL)-6,
interferon inducible protein (IP)-10, macrophage derived chemokine (MDC), platelet derived growth
factor (PDGF)-AA and regulated on activation normal T cell expressed and secreted (RANTES) levels were
found to be higher in OA compared to control SF (P < 0.001). Leptin, IL-13, macrophage inﬂammatory
protein (MIP)-1b, soluble CD40 (sCD40L) levels were higher and eotaxin and granulocyte colony-stimu-
lating factor (G-CSF) levels were lower in OA SF than in control SF, albeit borderline signiﬁcant (P < 0.05).
The PCA enabled identiﬁcation of six clusters of mediators, which explained 76% of the variance.
Conclusions: The current study provides the ﬁrst extensive proﬁle of cytokines, chemokines and growth
factors present in control and OA SF. Increased levels of mediators such as MDC and IL-6 imply
involvement of inﬂammatory processes and might be associated with the inﬂux of inﬂammatory cells in
OA synovial tissue. Moreover, the performed cluster analysis indicated multiple clusters, which could
indicate different pathophysiological pathways in the joint.
 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Summary
Soluble mediators, e.g., cytokines, chemokines and growth fac-
tors, are acknowledged as key players in the pathophysiology of
osteoarthritis (OA)1,2. However, a wide-spectrum screening of such
mediators in the joint environment is currently lacking. In this
study, synovial ﬂuid (SF) was collected from control donors and.-M. Zuurmond, TNO, Zerni-
erlands. Tel: 31-88-8666085;
-M. Zuurmond).
s Research Society International. Pend-stage knee OA patients and analysed for 47 cytokines, che-
mokines and growth factors using several multiplex ELISAs. In
addition, a principal component analysis (PCA) was performed to
cluster the measured mediators. Interleukin (IL)-6, interferon
inducible protein (IP)-10, macrophage derived chemokine (MDC),
platelet derived growth factor (PDGF)-AA and regulated on acti-
vation normal T cell expressed and secreted (RANTES) levels were
found to be higher in OA compared to control SF (P< 0.001). Leptin,
IL-13, macrophage inﬂammatory protein (MIP)-1b, soluble CD40
(sCD40L) levels were higher and eotaxin and granulocyte colony-
stimulating factor (G-CSF) levels were lower in OA SF than in
control SF, albeit at borderline signiﬁcance (P < 0.05). Increased
levels of inﬂammatory mediators and chemokines, such as MDCublished by Elsevier Ltd. All rights reserved.
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might be associated with the inﬂux of inﬂammatory cells in OA
synovial tissue. Additionally, the PCA enabled identiﬁcation of six
different clusters, which explained 76% of the variance, and in this
way could indicate different pathophysiological pathways in the
joint. This dataset is valuable as a reference for future experiments
to study pathophysiological pathways, and useful inmore extensive
proﬁling studies for OA.
Brief report
A control group of knee SF samples (n¼ 16) were collected from
post mortem donors within 24 h after death. Control donors had no
history of OA, other joint pathology and possessed macroscopic
healthy cartilage. OA SF samples (n ¼ 18) were collected during
total knee arthroplasty. All OA patients were diagnosed according
to the American College of Rheumatology (ACR) criteria for OA3.
Exclusion criteria were rheumatoid arthritis (RA) or infection. SF
samples were centrifuged at 3,000 rpm for 3 min to spin down any
cells or debris. The supernatant was stored at 80C until further
analysis. The control SF samples were stored for 1e10 years and OA
SF samples were stored for 1e3 years. None of the samples had ever
been thawed before. Collection of the SF was done according to the
Medical Ethical regulations of the University Medical Centre
Utrecht and according to the guideline ‘good use of redundant
tissue for clinical research’ constructed by the Dutch Federation of
Medical Research Societies on collection of redundant tissue forTable I
Overview of the measured mediator concentration (pg/ml) in control and osteoarthriti
percentage and lower limit of quantiﬁcation (LLOQ) with the number of samples are g
*P < 0.05 and #P < 0.001. GM-CSF, IL-12(p70), IL-13, IL-17, IL-2, IL-4, IL-5, IL-7, IL-9, TNF
Healthy SF
(median  IqR)
CV (%) <LLOQ
or 0 (n)
OA SF
(medi
EGF 4.8  13.1 102.3 11 4.8 
Eotaxin 14.6  39.6 96.0 6 0  0
Fibroblast growth
factor (FGF)-2
37.2  70.4 137.5 2 21.6 
Flt-3 ligand 135.9  119.7 59.0 0 103.5
Fractalkine 0  0 387.7 14 0  19
G-CSF 34.8  151 105.9 1 16.9 
Growth regulated
oncogene (GRO)
59.2  79.5 74.4 0 84.2 
IFNa2 7.2  10.5 67.4 7 16.4 
IFNg 40.7  12.9 23.30 0 28.0 
IL-10 3.3  6.3 127.6 6 2.1 
IL-12 (p40) 4.8  1.7 60.5 9 4.8 
IL-15 9.9  6.0 37.1 0 12.8 
IL-1a 0  1.8 217.8 9 0  4.
IL-1ra 0  6.9 125.6 8 0  0
IL-1b 0  1.5 205.4 11 4.8 
IL-3 0  0 0.0 16 4.8 
IL-6 4.8  0 196.9 13 135.8
IL-8 16.2  43.5 92.2 0 30  2
IP-10 302.1  280.8 107.6 0 710.4
MCP-1 542.4  839.2 102.1 0 824.8
MCP-3 4.8  36 123.5 10 4.8 
MDC 52.2  38.4 43.9 0 189.5
MIP-1a 4.8  0 26.7 16 4.8 
MIP-1b 9.6  24.0 83.7 5 21.8 
PDGF-AA 0  2.1 201.3 11 72.6 
PDGF-AB/BB 43.2  42.9 93.6 1 34.2 
RANTES 15.6  28.1 152.7 0 408.2
sCD40L 0  0 230.9 13 5.9 
sIL-2ra 37.5  76.8 90.8 1 63.0 
TGFa 0  0.6 201.2 9 0  0
HGF 2554.4  3505.7 80.2 0 2303
Leptin 82.2  1565.3 133.21 4 1637.5
Resistin 2713.4  1854.6 87.25 0 3824.8
Adiponectin >250,000 na na >250,
OSM 0  0 447.83 16 0  0research. As according to these guidelines, no information about
the patients’ characteristics could be obtained. Gender and age
informationwas available for limited donors. Control donors had an
average age of 39.6  9.3 and consisted of 55% female. OA donors
had an average age of 69.9  7.9 and consisted of 64 % female. Due
to the limited availability these data could not be linked to any of
the outcomes.
Two hundred microlitre of each of the OA SF samples was pre-
treated with 20 ml of hyaluronidase (Sigma, St. Louis, MO, USA;
10 mg/ml) for 15 min at 37C. Samples were spun down in a X-
column (Corning, Amsterdam, Netherlands; Costar 8169). Finally,
150 ml of the SF sample was dissolved in 300 ml high performance
ELISA (HPE)-0.1375% Tween (Sanquin, Amsterdam, Netherlands).
The pre-treated SF samples were used for all Multiplex ELISA assays
mentioned below.
To determine a wide panel of soluble mediators the commer-
cially available human inﬂammation 42-multiplex and the human
adipokine 13-multiplex (Millipore, Bellirica, MA, USA) were used
according to the manufacturer’s protocol. Additionally, 12 different
soluble mediators were measured with the Bio-Plex suspension
system (Bio-Rad laboratories, Hercules CA, USA) as previously
described4. The levels of cytokines in the SF samples were
expressed as pg/ml. All samples were measured in the same plate
and in duplo. Levels below the lower limit of quantiﬁcation (LLOQ)
were indicated as the value of the lowest point on the calibration
curve divided by 2. The measured mediators are listed in Table I.
Data are expressed as median  interquartile range (IqR) as thec (OA) SF. Data are indicated as median  IqR. The coefﬁcient of variation (CV) in
iven. Data are subjected to non-parametric statistical analysis ManneWhitney U;
a, TNFb, VEGF and NGF could not be detected
an  IqR)
CV (%) <LLOQ
or 0 (n)
Detection
limit
ManneWhitney
U (P-value)
0 189.3 14 5.3 0.65
236.7 15 12.1 *0.02
231.4 134.1 4 16.0 0.67
 76.4 53.1 0 6.1 0.23
168.5 12 7.6 0.14
15 66.9 0 3.9 *0.03
96 81.6 0 11.4 0.38
46.8 89.3 7 27.2 0.09
21.0 136.74 2 2.14 0.1
2.7 103.7 3 0.3 *0.04
11.9 137.7 10 12.4 0.30
5.7 31.2 0 0.6 0.32
9 153.4 12 1.5 0.74
288.4 14 2.3 0.14
11.9 298.6 14 0.7 0.61
0 179.3 16 9.8 0.18
 224.6 120.3 3 0.4 #0.001
3.5 170.9 0 0.3 0.24
 597.1 93.1 0 1.3 #0.001
 645.5 47.8 0 1.2 0.58
5 215.5 14 5.2 0.83
 119.8 41.8 0 2.4 #0.001
0 172.7 15 6.6 0.06
23.5 127.6 3 3.2 *0.04
116.9 72.8 0 0.3 #0.001
69.7 137.8 0 12.2 0.44
 910.9 114.3 0 1.6 #0.001
45.1 144.6 7 5.2 *0.005
72.5 65.9 0 7.5 0.11
401.5 17 1.4 0.4
 1695.2 38.12 0 1.6 0.32
 2414.1 125.33 0 27.4 *0.01
 3550.7 72.71 0 4.5 0.12
000 na na 80.3 na
307.79 12 1.59 0.09
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SPSS Inc. Chicago, IL, USA) was used for the statistical analysis.
For this study, a descriptive statistics approach was used for the
interpretation of the data due to the limited sample size. A Manne
Whitney U test was used to assess differences between control and
OA SF samples due to the predominantly non-Gaussian distribution
of the data. As a descriptive statistic approachwas used, values with
a P-value less than 0.001 were considered signiﬁcant. P-values
between 0.05 and 0.001 were considered borderline signiﬁcant.
No post-hoc correction for multiple testing was performed on the
data, due to the descriptive approach.
PCA was performed to enable identiﬁcation of clusters (i.e.,
components) of interrelatedmediators within the complete dataset.
Mediator levels were mean-centred to remove dependence on
magnitude of levels. Control and OA patient data were combined in
one single PCA analysis. Separate analysis of patients and controls
was judged impossible due to the limited number of subjects. Only
mediators with communalities >0.3 were included. Loading factors
were maximized using Direct oblimin rotation with Kaiser Normal-
isation. The optimum number of clusters was then decided based on
the scree-plot and eigenvalues (>1.0). Mediators were categorized
perclusterwhen their loading scoreswere>0.5. ACrohnbach’sawas
performed on each cluster to determine internal consistency.
This is one of the ﬁrst studies in which such a comprehensive
proﬁle of soluble mediators was measured in SF from (end-stage)
OA patients and control donors. With regard to previous studies,
the pattern of the mediator levels was found to be compatible for
OA donors. However, in these studies a small panel of mediators
was measured and the inclusion of control donors was lacking
(e.g.,5). Table I provides an overview of the measured levels of each
mediator (median  IqR). The majority of the soluble mediatorsTable II
Patternmatrix after oblimin rotationwith Kaiser Normalisation as obtained from PCA in th
loading factors >0.5 are displayed
Action Mediator Cluster
1 2
Pro-inﬂammatory IFNg 0.988
Pro-inﬂammatory OSM 0.980
Pro-inﬂammatory IL-7 0.971
Pro-inﬂammatory IL-1b 0.947
Anti-inﬂammatory IL-1ra 0.851
Chemokine MCP-3 0.849
Pro-inﬂammatory IL-8 0.823
Growth factor TGFa 0.612
Pro-inﬂammatory IL-3 0.9
Chemokine MIP-1a 0.9
Proliferation EGF 0.8
Adipokine Leptin 0.8
Proliferation IL-12 0.7
Chemokine MCP-1
Anti-inﬂammatory IL-10
Chemokine Eotaxin
Chemokine G-CSF
Chemokine RANTES
Growth factor PDGF-AB/BB
Growth factor PDGF-AA
Chemokine IP-10
Growth factor sCD40L
Pro-inﬂammatory IFNa
T-cell factor Flt-3 ligand
Growth factor HGF
T-cell factor IL-15
T-cell factor sIL-2ra
Adipokine IL-6
Adipokine Resistin
Eigenvalues 10.5 5.8
Variances explained (%) 30% 17%
Cronbach’s alphas 0.835 0.0could be detected in the SF samples of both control and OA donors.
Of the 47 measured mediators, ﬁve mediators were present at
signiﬁcantly different levels in OA compared to control SF. The
levels of the chemokinesMDC, RANTES and IP-10, the growth factor
PDGF-AA and the pro-inﬂammatory cytokine IL-6 were signiﬁ-
cantly higher in OA than in control SF (P< 0.001). In addition, levels
of the adipokine leptin, the chemokine MIP-1b, and the pro-
inﬂammatory cytokine sCD40L were higher and levels of the che-
mokine eotaxin and the growth factor G-CSF were lower in OA than
in control SF, albeit all with borderline signiﬁcance (P < 0.05).
The PCA was performed to gain insight into the associations
between individual mediators that were assessed. The PCA showed
communalities >0.3, which as such, were included in the analysis.
PCA enabled identiﬁcation of six clusters of interrelated mediators
among the spectrum of 47 mediators (Table II). These clusters may
reﬂect important pathophysiological pathways in the joint. In the
pattern matrix, the mediators interferon (IFN)g, oncostatin M
(OSM), IL-7, IL-1b, IL-8 and transforming growth factor (TGF)awere
clustered in the ﬁrst cluster, and together explained 30.2 % of the
total variance with an eigenvalue of 10.5. Cluster 2 included IL-3,
MIP-1a, epidermal growth factor (EGF), leptin and IL-12 (variance
explained 16.8%, eigenvalue 5.9). Cluster 3, contained monocyte
chemoattractant protein (MCP)-1, IL-10, eotaxin and G-CSF (vari-
ance explained 10.8%; eigenvalue 3.8). Cluster 4 contained RANTES,
PDGF-AB/BB, PDGF-AA, sCD40L, IP-10, IFNa (variance explained
6.4%, eigenvalue 2.2). Cluster 5 included Fms-like tyrosine kinase 3
(Flt-3) ligand, hepatocyte growth factor (HGF), IL-15 and sIL-2ra
(variance explained 6.1%, eigenvalue 2.1). Cluster 6 included the
adipokines IL-6 and resistin (variance explained 6.0%, eigenvalue
2.1). In total, these six clusters explained more than 76% of the
variance. The ﬁrst two clusters mainly contained pro-inﬂammatorye spectrum of SFmediators. Control and osteoarthritic samples were combined. Only
3 4 5 6
42
19
88
71
02
0.841
0.807
0.653
0.622
0.953
0.935
0.914
0.705
0.683
0.589
0.827
0.795
0.703
0.565
0.922
0.678
3.8 2.2 2.1 2.1
11% 6% 6% 6%
59 0.114 0.615 0.070 0.115
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Cluster 4 contained predominantly growth factors and cluster 5
factors associated with T-cell proliferation and maturation. Finally,
cluster 6 contained only adipokines. Mediators in all these six
clusters are known to be part of important processes in the joint
homoeostasis. However, distinguishing between potential clusters
was difﬁcult, since these mediators are involved in adjacent and
interrelated pathways.
Cytokines, chemokines, adipokines and growth factors play a
major role in inﬂammatory diseases, such as OA, and are currently
intensively studied. The adipokines are associated with obesity,
which is in itself associated with low-grade systemic inﬂammation,
one of the risk factors for the development and progression of
OA2,6,7. The different levels of IL-6, leptin and adiponectin between
control and OA SF might indicate a role for certain adipokines in OA
processes, which is in line with literature7. However, these data
were not corrected for body mass index (BMI), which might in-
ﬂuence the outcomes. Another group of mediators consisted of
chemokines. The measured chemokines such as the related Che-
mokineseChemokines (CC) mediators RANTES, MDC, MIP-1a and
MIP-1b were higher in OA than in control SF. This group of che-
mokines share the same receptor complexes, e.g., chemokines-
chemokines receptor (CCR)1, CCR2 and CCR58 and their major
function is to attract inﬂammatory cells, e.g., T-cells, macrophages
and other inﬂammatory cells to sites of inﬂammation. Chemokines,
such as RANTES, are also capable of activating (inﬂammatory) cells
in the production of inﬂammatory mediators. As shown in previous
studies, RANTES promotes the production of IL-6 by synovial ﬁ-
broblasts and enhances the inﬂammatory response in OA through
the different CCR receptor in synovial tissue9. Moreover, CCR re-
ceptors are present in chondrocytes and treatment of cartilage
explants with RANTES was demonstrated to increase release of
proteoglycans10. The combination of multiple CC-chemokines in
combination with IL-6 and leptin in the SF was not demonstrated
earlier. Blocking these CC-chemokines or their receptors in OA
might reduce IL-6 and leptin production and, consequently, the
inﬁltration of inﬂammatory cells and the production of catabolic
factors in the joint. Future research is necessary to elucidate this.
In none of the SF samples granulocyte macrophage colony-
stimulating factor (GM-CSF), IL-12(p70), IL-13, IL-17, IL-2, IL-4, IL-
5, IL-7, IL-9, tumor necrosis factor (TNF)b, vascular endothelial
growth factor (VEGF) and nerve growth factor (NGF) and TNFa,
could be detected. IL-1 was only detected at very low levels. TNFa
and IL-1 are pro-inﬂammatory cytokines, which are associatedwith
cartilage degeneration, synovial inﬂammation and bone changes11.
Although in some in vivo animal models of OA, blocking IL-1 or
TNFa gave promising results, this could not be validated in clinical
studies12. Our results likewise do not support a prominent role for
IL-1 and TNFa in end-stage OA patients. Nonetheless, this does not
exclude a role for IL-1 and TNFa in for example early OA, as OA has a
heterogeneous character with multiple phenotypes.
For the interpretation of the data it should be mentioned that
our results are based on a small sample size, due to donor avail-
ability, which were not paired on age, BMI and sex. Moreover, it
should be taken into account that ex-vivo modiﬁcations cannot be
excluded for the control donors as samples were taken after death.
Also due to the small sample size, no further statistics were per-
formed on the PCA to study differences between the clusters for OA
and control SF samples. Therefore this pilot dataset should be
regarded as a reference and more extensive proﬁling studies are
necessary to conﬁrm these data.
In summary, this is the ﬁrst study measuring a wide panel of
mediators in the SF of both control and end-stage OA donors.
Increased levels of mediators such as MDC, IL-6 and RANTES once
more conﬁrm involvement of inﬂammatory processes andmight beassociated with the inﬂux of inﬂammatory cells in OA synovial
tissue. In addition, the PCA indicated 6 clusters, which reﬂect
different processes in the joint. Due to the small samples size no
hard conclusions can be drawn. Nonetheless, this pilot dataset
provides a valuable reference for future experiments to study
pathophysiological pathways, and to be useful in more extensive
proﬁling studies for OA.
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